期刊
AMERICAN JOURNAL OF ROENTGENOLOGY
卷 193, 期 1, 页码 55-60出版社
AMER ROENTGEN RAY SOC
DOI: 10.2214/AJR.09.2553
关键词
contrast-enhanced ultrasound; contrast media; FDA approval; radiology practice guidelines; ultrasound contrast agents
资金
- Lantheus Medical Imaging
OBJECTIVE. Although ultrasound contrast agents (UCAs) are popular and widely used in Europe and Asia, the U. S. Food and Drug Administration (FDA) has not approved a microbubble agent for radiology imaging in the United States. Herein, we discuss the evidence for and the obstacles to using UCAs for contrast-enhanced ultrasound (CEUS). CONCLUSION. Despite the obstacles to the use of UCAs for CEUS including regulatory and practice patterns, the evidence indicates that radiologists and patients will be missing an effectual imaging option if we do not encourage the use of CEUS and strongly support the approval of UCAs by the FDA. The evidence outweighs the obstacles: CEUS is cost-effective; can be performed at the bedside; uses no ionizing radiation; has no nephrotoxicity; and, most importantly, can provide accurate diagnostic information comparable to CT and MRI.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据